Robertson J, et al. - This study aimed to characterize the metabolic pathways underlying decreased serum low-density lipoprotein cholesterol (LDL-c) lipid changes. The outcome of this study suggests that the patients with rheumatoid arthritis (RA) have low serum LDL-c because of hypercatabolism of LDL particles. IL-6 blockade normalises this catabolism in a manner connecting with the acute phase response (and thus hepatic IL-6 signalling) but not with RA disease activity as measured clinically. They show that IL-6 is one of the key drivers of inflammation-driven dyslipidaemia.